Welcome to our dedicated page for Tectonic Therapeutic SEC filings (Ticker: TECX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode Tectonic Therapeutic’s dense SEC paperwork? Clinical-stage biotech reports are packed with GPCR science, trial data tables and dilution disclosures that can bury the R&D story investors need. Each 10-K or S-1 from Tectonic Therapeutic (TECX) runs hundreds of pages, while Form 4 insider trades may hint at management’s confidence long before headline news.
Stock Titan solves that problem. Our AI engine turns every Tectonic Therapeutic quarterly earnings report 10-Q filing, 8-K material events, and proxy statement executive compensation section into plain-English highlights you can scan in minutes. Receive real-time alerts the moment a Tectonic Therapeutic Form 4 insider transactions real-time update posts to EDGAR, jump straight to cash-runway notes, or view a chart that links R&D spend to milestone payments. Natural-language answers like “understanding Tectonic Therapeutic SEC documents with AI” appear beside each section so you never hunt for definitions again.
Whether you’re tracking a shelf registration, analysing Tectonic Therapeutic earnings report filing analysis, or comparing option grants from the Tectonic Therapeutic proxy statement executive compensation, our platform keeps every document in context. You can even bookmark “Tectonic Therapeutic annual report 10-K simplified” or monitor “Tectonic Therapeutic insider trading Form 4 transactions” to catch buying or selling trends before the market reacts. All filings—10-K, 10-Q, 8-K, S-1, DEF 14A—arrive within seconds and are paired with expert commentary, giving you the clarity to act, not just read.
Tectonic Therapeutic (TECX) reported a communications update. The company posted a presentation titled “TX45 Phase 1b (Part B) PH-HFrEF Data Release Single Dose Hemodynamic Trial” and issued a press release announcing positive topline data from the Phase 1b Part B clinical trial of TX45 in patients with Group 2 pulmonary hypertension in HFrEF.
The presentation is furnished as Exhibit 99.1, and the press release is furnished as Exhibit 99.2 and, other than the quotes contained therein, is incorporated by reference. No financial results or transaction terms were disclosed in this update.
Tectonic Therapeutic insider filing: Marc Schwabish, the company's Chief Business Officer and a director, reported equity awards on 09/25/2025. He received 4,210 restricted stock units (RSUs) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, contingent on continued service. He was also granted an employee stock option for 7,650 shares with a $14.71 exercise price that vests in 48 equal monthly installments beginning 10/25/2025 and expires 09/24/2035. The reported shares and options are held directly and the RSUs were issued at no cash price.
Tectonic Therapeutic insider Peter McNamara, the company's Chief Scientific Officer and a director, reported equity awards on 09/25/2025. He was granted 4,550 restricted stock units (RSUs) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, and an employee stock option to purchase 8,260 shares at an exercise price of $14.71 per share that vests monthly over 48 months beginning 10/25/2025 and expires 09/24/2035. After these grants, McNamara directly beneficially owns 33,879 shares and 8,260 option shares underlying the option.
Insider grant and option award reported. Tectonic Therapeutic CFO Daniel Lochner acquired 5,430 restricted stock units (RSUs) on 09/25/2025 that convert one-for-one into common stock and vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, contingent on continued service. He also received an employee stock option to buy 9,860 shares with a $14.71 exercise price, exercisable beginning 09/24/2025 and expiring 09/24/2035; the option vests monthly over 48 months starting 10/25/2025. Following the transactions, Mr. Lochner beneficially owns 28,121 shares (corrected from a prior filing amount).
Marcella K. Ruddy, Chief Medical Officer of Tectonic Therapeutic, Inc. (TECX), received equity awards on 09/25/2025. The filing shows a grant of 5,370 restricted stock units (each convertible to one share) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, subject to continued service. An employee stock option with a $14.71 exercise price covering 9,750 shares was also granted on 09/25/2025; those options vest in 48 equal monthly installments beginning 10/25/2025 and expire 09/24/2035. After these transactions, Ms. Ruddy beneficially owns 55,311 shares. The Form 4 is signed by an attorney-in-fact on 09/29/2025.
Tectonic Therapeutic CEO and director Reicin Alise reported multiple equity awards and holdings on Form 4. The filing shows acquisition on 09/25/2025 of 14,700 restricted stock units (RSUs) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, subject to continued service. The reporting person also holds an employee stock option to buy 26,710 shares at $14.71 per share exercisable beginning 09/25/2025 with expiration 09/24/2035; the option vests monthly over 48 installments starting 10/25/2025.
The report discloses 228,185 shares beneficially owned directly after the RSU acquisition and 124,530 shares held indirectly by the Reicin-Boiarsky Family Trust, where the reporting person may share voting and dispositive power but disclaims beneficial ownership except to extent of pecuniary interest.
FAQ
What is the current stock price of Tectonic Therapeutic (TECX)?
What is the market cap of Tectonic Therapeutic (TECX)?
